{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:06:41Z","timestamp":1791202001401,"version":"4.2.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T00:00:00Z","timestamp":1667692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T00:00:00Z","timestamp":1667692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-022-02420-5","type":"journal-article","created":{"date-parts":[[2022,11,6]],"date-time":"2022-11-06T17:02:40Z","timestamp":1667754160000},"page":"699-706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The impact of complete clearance and almost complete clearance of psoriasis on quality of life: a literature review"],"prefix":"10.1007","volume":"315","author":[{"given":"Nicole D.","family":"Boswell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison K.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther A.","family":"Balogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,6]]},"reference":[{"issue":"5","key":"2420_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.36849\/JDD.2020.4957","volume":"19","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Wu JJ, Armstrong A, Menter A, Liu C, Jacobson A (2020) Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. J Drugs Dermatol 19(5):487\u2013492","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"2420_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4103\/0378-6323.48689","volume":"75","author":"S Aghaei","year":"2009","unstructured":"Aghaei S, Moradi A, Ardekani GS (2009) Impact of psoriasis on quality of life in Iran. Indian J Dermatol Venereol Leprol 75(2):220. https:\/\/doi.org\/10.4103\/0378-6323.48689","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"8","key":"2420_CR3","doi-asserted-by":"publisher","DOI":"10.5070\/D3208023523","volume":"20","author":"SR Feldman","year":"2014","unstructured":"Feldman SR, Malakouti M, Koo JY (2014) Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online J 20(8):13030\/qt48r4w8h2","journal-title":"Dermatol Online J"},{"issue":"1","key":"2420_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2016.03.026","volume":"75","author":"B Strober","year":"2016","unstructured":"Strober B, Papp KA, Lebwohl M et al (2016) Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 75(1):77\u201382. https:\/\/doi.org\/10.1016\/j.jaad.2016.03.026","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2420_CR5","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/09546634.2017.1329501","volume":"28","author":"D Norris","year":"2017","unstructured":"Norris D, Photiou L, Tacey M et al (2017) Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population. J Dermatol Treat 28(8):731\u2013736. https:\/\/doi.org\/10.1080\/09546634.2017.1329501","journal-title":"J Dermatol Treat"},{"issue":"1","key":"2420_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.4103\/ijp.IJP_166_16","volume":"49","author":"VV Karamata","year":"2017","unstructured":"Karamata VV, Gandhi AM, Patel PP, Sutaria A, Desai MK (2017) A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life. Indian J Pharmacol 49(1):84\u201388. https:\/\/doi.org\/10.4103\/ijp.IJP_166_16","journal-title":"Indian J Pharmacol"},{"issue":"2","key":"2420_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2340\/00015555-3048","volume":"99","author":"MK Rasmussen","year":"2019","unstructured":"Rasmussen MK, Enger M, Dahlborn AK et al (2019) The importance of achieving clear or almost clear skin for patients: results from the Nordic countries of the global. Acta Derm Venereol 99(2):158\u2013163. https:\/\/doi.org\/10.2340\/00015555-3048","journal-title":"Acta Derm Venereol"},{"key":"2420_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1772454","author":"NJ Korman","year":"2020","unstructured":"Korman NJ, Malatestinic W, Goldblum OM et al (2020) Assessment of the benefit of achieving complete versus almost complete skin clearance in psoriasis: a patient\u2019s perspective. J Dermatol Treat. https:\/\/doi.org\/10.1080\/09546634.2020.1772454","journal-title":"J Dermatol Treat"},{"issue":"5 Pt 1","key":"2420_CR9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1067\/mjd.2000.103983","volume":"42","author":"SN Al-Suwaidan","year":"2000","unstructured":"Al-Suwaidan SN, Feldman SR (2000) Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 42(5 Pt 1):796\u2013802. https:\/\/doi.org\/10.1067\/mjd.2000.103983","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2420_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3109\/09546634.2015.1093589","volume":"27","author":"SR Feldman","year":"2016","unstructured":"Feldman SR, Bushnell DM, Klekotka PA et al (2016) Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatol Treat 27(3):224\u2013227. https:\/\/doi.org\/10.3109\/09546634.2015.1093589","journal-title":"J Dermatol Treat"},{"issue":"3","key":"2420_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/09546634.2014.943687","volume":"26","author":"HN Viswanathan","year":"2015","unstructured":"Viswanathan HN, Chau D, Milmont CE et al (2015) Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis. J Dermatol Treat 26(3):235\u2013239. https:\/\/doi.org\/10.3109\/09546634.2014.943687","journal-title":"J Dermatol Treat"},{"issue":"4","key":"2420_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jaad.2014.05.001","volume":"71","author":"J Takeshita","year":"2014","unstructured":"Takeshita J, Callis Duffin K, Shin DB et al (2014) Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. J Am Acad Dermatol 71(4):633\u2013641. https:\/\/doi.org\/10.1016\/j.jaad.2014.05.001","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2420_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000365390","volume":"230","author":"MK Basra","year":"2015","unstructured":"Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY (2015) Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 230(1):27\u201333. https:\/\/doi.org\/10.1159\/000365390","journal-title":"Dermatology"},{"issue":"10","key":"2420_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s00403-008-0885-7","volume":"300","author":"K Reich","year":"2008","unstructured":"Reich K, Griffiths CE (2008) The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Arch Dermatol Res 300(10):537\u2013544. https:\/\/doi.org\/10.1007\/s00403-008-0885-7","journal-title":"Arch Dermatol Res"},{"issue":"4","key":"2420_CR15","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jaad.2019.06.018","volume":"81","author":"A Egeberg","year":"2019","unstructured":"Egeberg A, Thyssen JP (2019) Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis. J Am Acad Dermatol 81(4):943\u2013949. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.018","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2420_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/09546634.2018.1544408","volume":"31","author":"TA Kouwenhoven","year":"2020","unstructured":"Kouwenhoven TA, van der Ploeg JAM, van de Kerkhof PCM (2020) Treatment goals in psoriasis from a patient perspective: a qualitative study. J Dermatol Treat 31(1):13\u201317. https:\/\/doi.org\/10.1080\/09546634.2018.1544408","journal-title":"J Dermatol Treat"},{"issue":"12","key":"2420_CR17","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/jdv.15065","volume":"32","author":"A Armstrong","year":"2018","unstructured":"Armstrong A, Jarvis S, Boehncke WH et al (2018) Patient perceptions of clear\/almost clear skin in moderate-to-severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. J Eur Acad Dermatol Venereol 32(12):2200\u20132207. https:\/\/doi.org\/10.1111\/jdv.15065","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"2420_CR18","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.jaad.2018.09.019","volume":"80","author":"O Ogbechie-Godec","year":"2019","unstructured":"Ogbechie-Godec O, Azarchi S, Lee J, Cohen DE, Neimann A, Nagler AR (2019) Validated patient-reported outcome measurements for psoriasis may not reflect patients\u2019 current preferences. J Am Acad Dermatol 80(5):1445\u20131447. https:\/\/doi.org\/10.1016\/j.jaad.2018.09.019","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2420_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3109\/09546634.2015.1034071","volume":"26","author":"TL Kauf","year":"2015","unstructured":"Kauf TL, Yang JC, Kimball AB et al (2015) Psoriasis patients\u2019 willingness to accept side-effect risks for improved treatment efficacy. J Dermatol Treat 26(6):507\u2013513. https:\/\/doi.org\/10.3109\/09546634.2015.1034071","journal-title":"J Dermatol Treat"},{"issue":"4","key":"2420_CR20","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jaad.2016.10.040","volume":"76","author":"M Hawro","year":"2017","unstructured":"Hawro M, Maurer M, Weller K et al (2017) Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. J Am Acad Dermatol 76(4):648\u201354.e2. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.040","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2420_CR21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/j.1365-2133.2007.08071.x","volume":"157","author":"F Sampogna","year":"2007","unstructured":"Sampogna F, Tabolli S, Abeni D (2007) The impact of changes in clinical severity on psychiatric morbidity in patients with psoriasis: a follow-up study. Br J Dermatol 157(3):508\u2013513. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08071.x","journal-title":"Br J Dermatol"},{"issue":"2","key":"2420_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1468-3083.2012.04451.x","volume":"27","author":"D B\u00f6hm","year":"2013","unstructured":"B\u00f6hm D, Stock Gissendanner S, Bangemann K et al (2013) Perceived relationships between severity of psoriasis symptoms, gender, stigmatization and quality of life. J Eur Acad Dermatol Venereol 27(2):220\u2013226. https:\/\/doi.org\/10.1111\/j.1468-3083.2012.04451.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2420_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21051690","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y (2020) Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21051690","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2420_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1080\/09546634.2017.1329499","volume":"28","author":"AO Fairchild","year":"2017","unstructured":"Fairchild AO, Reed SD, Johnson FR, Anglin G, Wolka AM, Noel RA (2017) What is clearance worth? Patients\u2019 stated risk tolerance for psoriasis treatments. J Dermatol Treat 28(8):709\u2013715. https:\/\/doi.org\/10.1080\/09546634.2017.1329499","journal-title":"J Dermatol Treat"},{"issue":"6","key":"2420_CR25","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1080\/09546634.2017.1294727","volume":"28","author":"BE Elewski","year":"2017","unstructured":"Elewski BE, Puig L, Mordin M et al (2017) Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75\u201389 response: results from two phase 3 studies of secukinumab. J Dermatol Treat 28(6):492\u2013499. https:\/\/doi.org\/10.1080\/09546634.2017.1294727","journal-title":"J Dermatol Treat"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02420-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-022-02420-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-022-02420-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T11:05:50Z","timestamp":1681124750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-022-02420-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,6]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["2420"],"URL":"https:\/\/doi.org\/10.1007\/s00403-022-02420-5","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,6]]},"assertion":[{"value":"15 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Feldman has received research, speaking and\/or consulting support from Eli Lilly and Company, GlaxoSmithKline\/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen Inc, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Valeant, Menlo, Merck & Co, Qurient Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Advance Medical, Suncare Research, Informa, UpToDate and the National Psoriasis Foundation. He is also the founder and majority owner of  [drscore.com] and the founder and part owner of Causa Research. Nicole D. Boswell, Esther A. Balogh and Madison K. Cook have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}